Multiple myeloma

Autor: Jesús F. San-Miguel, U. Mey, Mario Boccadoro, Thierry Facon, Roman Hájek, P. Moreau, M.V. Mateos, E. Terpos, M.A. Dimopoulos, Michele Cavo, Fredrik Schjesvold, H. Goldschmidt, Gordon Cook, Michel Delforge, Sonja Zweegman, H. Einsele, Pieter Sonneveld

Publikováno v: EHA Guidelines Committee & ESMO Guidelines Committee 2021, ' Multiple myeloma : EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † ', Annals of Oncology, vol. 32, no. 3, pp. 309-322 . https://doi.org/10.1016/j.annonc.2020.11.014
Annals of Oncology, 32(3), 309-322. Oxford University Press
Annals of Oncology, 32(3), 309-322. Elsevier Ltd.
Dimopoulos, M A, Moreau, P, Terpos, E, Mateos, M V, Zweegman, S, Cook, G, Delforge, M, Hájek, R, Schjesvold, F, Cavo, M, Goldschmidt, H, Facon, T, Einsele, H, Boccadoro, M, San-Miguel, J, Sonneveld, P & Mey, U 2021, ' Multiple Myeloma : EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up ', HemaSphere . https://doi.org/10.1097/HS9.0000000000000528
HemaSphere

ispartof: HEMASPHERE vol:5 issue:2 ispartof: location:United States status: published

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f60c3c6609190b33f4f46700bb41d85c
https://pure.eur.nl/en/publications/9ef136fc-4fcf-4dc0-ba1f-c56b9dd51cd7

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)

Autor: F. Hitz, M. Kraus, T. Pabst, D. Hess, L. Besse, T. Silzle, U. Novak, K. Seipel, S. Rondeau, S. Stüdeli, S. Berardi Vilei, P. Samaras, U. Mey, C. Driessen, for the Swiss Group for Clinical Cancer Research SAKK

Publikováno v: Blood Cancer Journal, Vol 9, Iss 9, Pp 1-8 (2019)
Hitz, F; Kraus, M; Pabst, Thomas; Hess, D; Besse, L; Silzle, T; Novak, Urban; Seipel, Katja; Rondeau, S; Stüdeli, S; Vilei, S Berardi; Samaras, P; Mey, U; Driessen, C (2019). Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10). Blood cancer journal, 9(9), p. 70. Springer Nature 10.1038/s41408-019-0228-2
Blood Cancer Journal

The antiretroviral agent nelfinavir has antimyeloma activity and can overcome resistance to bortezomib. Our phase I/II trial investigated whether adding nelfinavir to lenalidomide–dexamethasone can overcome lenalidomide resistance in lenalidomide-r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b09dcc16e1fd8629234b44651d327686
http://link.springer.com/article/10.1038/s41408-019-0228-2

Integrating novel agents into multiple myeloma treatment – current status in Switzerland and treatment recommendations

Autor: C Taverna, M Bargetzi, D Betticher, J Gmür, M Gregor, U Hess, N Ketterer, E Lerch, T Matthes, U Mey, T Pabst, C Renner

Publikováno v: Swiss Medical Weekly, Vol 140, Iss 3738 (2010)

The treatment of multiple myeloma has undergone significant changes in the recent past. The arrival of novel agents, especially thalidomide, bortezomib and lenalidomide, has expanded treatment options and patient outcomes are improving significantly.

Externí odkaz: https://doaj.org/article/5720a28143ee47f8b2e120a562ef7699

ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma

Autor: Michael Pfreundschuh, Pierre Soubeyran, U. Mey, V. Goede, Emanuele Zucca, Gustaaf W. van Imhoff, M. Trněný, Marek Trněný, P. Fields, Ulrich Wedding, Christian Buske, Stefano Luminari, Marco Ladetto, Christiane Pott, Paul Fields, Steven Le Gouill, Gianluca Gaidano, Anna Sureda Balari, Jan Walewski, Reinhard Stauder, Michele Spina, Martin Hutchings, Valentin Goede, M. Ladetto, Ulrich Mey, Peter de Nully Brown, R. Stauder, Norbert Schmitz, Andrés J.M. Ferreri, Martin Dreyling, Michael J. Hutchings, Alberto Zamò, P. Soubeyran, M. Spina

The European Society for Medical Oncology (ESMO) consensus conference on mature B cell lymphomas and chronic lymphocytic leukaemia (CLL) was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of 25 leading experts. Th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14bb5282a980ce60ce22ac508f96b78e
https://hdl.handle.net/11380/1153066